Drug Profile


Alternative Names: BAY 1841788; ODM 201

Latest Information Update: 04 Jul 2017

Price : $50

At a glance

  • Originator Orion
  • Developer Bayer HealthCare; Orion; Swiss Group for Clinical Cancer Research
  • Class Amides; Antiandrogens; Antineoplastics; Pyrazoles; Small molecules
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 04 Jul 2017 Chemical structure information added
  • 10 Mar 2017 Phase-II clinical trials in Prostate cancer (Metastatic disease, Second-line therapy or greater) in Switzerland (PO) (NCT02933801)
  • 15 Feb 2017 Phase-I clinical trials in Prostate cancer (In volunteers) in Germany (PO) (NCT03048110)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top